EnlitenAI

Raising $200K to fund clinical trials and build AI driven use cases in our Cloud platform aimed at managing Seizures/Neurological conditions.

Facebook Twitter LinkedIn

Pitch Deck & Product Demo Link:
http://bit.ly/Inception-EnlitenAI

About EnlitenAI:
EnlitenAI is building an AI driven Platform (Neuroliten) for Neurological conditions aimed at better Management and Treatment of Seizures/Epilepsy. We have potential independent revenue streams from Insurance Carriers (reduced cost burden), Pharma Co (drug efficacy trials) and Neurologists (wearables based patient vitals monitoring). We are pre Revenue, at the moment.

Who We are:
SaaS Product startup that has built a Connected Platform (NeuroLiten) with context rich data to provide AI driven valuable insights for effective management & personalized treatment of Neurological conditions (immediate focus on Epilepsy/Seizures)

Our Vision:
Our vision is to create a scalable platform that creates a novel way of patient vitals monitoring based healthcare delivery for management/treatment of Neurological conditions leveraging Wearables & Connected Everything for Personalized Healthcare.

Our Team:
  • Dr. Himanshu Misra (CEO, Co-founder) PhD Univ of Illinois, Urbana.  20+yrs Seizure management, HPC, AI, IoT, Digital & Numerical Modeling, Patents filed, successful exits
  • Mr. Navaneeth Seshadri (CTO, co-founder) MS. Boston University. 16yrs experience, AI/ML/Deep Learning technologies, Digital Transformation, patents filed, successful exits
  • Dr. Clint Nelson, MD, Professor - Neurology, Univ of Utah
  • Dr. Amy Renee Borentstein, Professor - Epidemiology & Public Health, UCSD
  • Dr. Walter Greenleaf, Neuroscientist, Stanford University, Digital Health & Human behavior
  • Mr. David Bradford, CEO - Fluentworlds, Advisor & Fund Raising
  • Dr. James Mortimer, Professor Emeritus - Epidemiology & Parkinsons, USF
  • Mr. John Sheeran, COO, Interaxon (Digital Health)

Our Market Focus:
Immediate Term ($40 Billion Cost burden in US) - Seizure Management & Wellness
Long Term: ANY Neurological condition ($ 1Trillion Cost Burden in US) Autism, ADD, Parkinson's, Behavioral & Psychological disorders, Mental health

The Problems We Address:
  1. Inability to Access or share context rich valuable information:
    1. Ensure Patient safety
    2. Ensure timely response/intervention
    3. Stream full details of seizure episodes to Neurologists, real-time
    4. Continuous patient monitoring using non FDA wearables
  2. Lack of Personalization of Wellness/care:
    1. Patient Epilepsy Diaries
    2. Personalized Treatment
    3. Drug titration - patient specific
    4. Neuroplasticity - patient specific
    5. Trial & Error cycles - patient specific
    6. Advanced prediction & correlation modeling
  3. Rising Cost Burden:
    1. No of ER visits
    2. Duration of hospitalizations
    3. Improved drug efficacy
    4. Reduced disability claims
Stakeholders we Impact:
  1. Patients & Caregivers
  2. Neurologists
  3. 1st Responders
  4. Insurance Carriers
  5. Pharma Companies
  6. Biomedical Devices Companies

Five INDEPENDENT Revenue Streams Exist (Total revenue forecast in 1 year after clinical trials& product launch ~ $138M)
  1. Neurologists Stream (total of 37K Neuroscientists in US) - $9.8M
    1. Better vital monitoring, complete visibility of episode specific data (Neurologists are never present when seizures happen!) leading to better treatment/care
    2. One time license payment.  Plus, monthly subscription per patient & AI/Analytics
  2. Insurance Carriers - $106M
    1. Preemptive intervention, less severe symptoms, reduced ER visits & hospitalizations.  Participative engagement for enhanced wellness
    2. One time fee for each patient plus monthly fees per patient for monitoring & AI/Analytics
  3. Patients/Caregiver stream (US Epilepsy population is 4Million) - $3.5M
    1. Assurance that help is round the corner.  Ability to share episode specific real time data and access dashboards for past seizure histories./diaries  Preemptive alert notifications.  Shorter trial & errors
    2. FREE (no set up fees).  Only a nominal $10/month subscription fee per patient for monitoring & AI/Analytics
  4. Pharma Companies Stream - $6.6M
    1. Enhanced drug efficacy, more comprehensive hypotheses, successful launch of new Anti Epileptic Drugs (AEDs)
    2. One time fee for patient onboarding, plus monthly subscription per patient for monitoring  & AI/Analytics
  5. Wearable OEMs - $3.3M
    1. Revenue sharing in co-selling engagements
    2. Digital marketing & pay per click revenues for any smartwatch (Apple6, Fitbit, Samsung watch, Muse headband, TicWatch...all Google WearOS & iOS wearables)

 In summary (Total revenue of $138M)
(1) Neurologists Stream - $9.8M
One time (per neurologist): $ 500
Monthly monitoring per patient: $ 50 
Assumption: Mobilize 1800 US Neurologists (5% of US) 

(2) Insurance Carrier Stream - $106M
One time (per patient): $ 1000 
Monthly payment (per patient): $ 50
Mobilize One Insurance company ~90,000 Epilepsy patients (2.5% US Epilepsy patient base)

(3) Patients/Caregivers Stream - $3.5M
One time (per patient): $ 0 
Monthly payment (per patient): $ 10
Enlist ~90,000 epilepsy patients/family caregivers (2.5% US Epilepsy patient base) 
 
(4) Pharma Companies Stream - $ 6.6M
One time (per patient): $ 1000 
Monthly payment (per patient): $ 100 
3 Drug efficacy trials and 1000 patients in each trial
 
(5) Wearables OEMs Stream - $3.3M 
Co-selling revenue sharing: 10% device price 
Assume 10% co-selling revenue sharing for 50% of patients
Pay-per-click revenue - difficult to quantify

Market Mobilization:
  1. 2021: 
    1. Focus on US market
    2. Focus on Epilepsy
    3. Mobilize ~1800 Neurologists (5% of US Neurologists)
    4. Mobilize ~2 Insurance Carriers to target ~60K patients (1.5% US population)
    5. Target 3 Trials with Pharma Companies (1000 patients each)
    6. Enhance AI Modeling & features
    7. Link global Neurology/EEG databases
  2. 2022
    1. Continue footprint expansion in US market for Epilepsy
    2. Establish relationships to create low cost wearables that are purpose built for epilepsy
    3. Link genomic databases for understanding genetic predisposition
    4. Scale out to Autism/ADD and behavioral/neurological conditions
    5. Scale up to other Geos with low cost devices 
Long term Vision:
  • To become the de facto standard wherein multiple point solution from others can get integrated into our platform empowering all stakeholders to take better decisions.  Get accepted for situations of immediate exposure such as the Covid-19 pandemic where continuous monitoring vital parameters is critical.
Funding
We have raised some funds  ($95K) from our friends & contacts that were used to build our prototype.
We have also raised $100K from AWS thru NVIDIA's Inception program that may be used as credits towards our Infrastructure costs 

Use of New Money
Seed Series (May - July'21): $250K 
Series A       (Aug '21) : $1M
  1. Product Development - Artificial Intelligence modeling & Features
  2. Clinical trials 
  3. IP creation & protection
  4. Business Development & Sales
  5. Marketing
  6. Compliance & Certifications


Ready to Ask For Funding for your company?

Post a Funding Request

EnlitenAI is no longer seeking funding.

Key Facts

Industry
{{model.industry | ffIndustry}}
Location
{{model.city_state}}
Year Founded
{{model.year_founded}}
Monthly Income
{{model.monthly_income | ffIncome}}
Website
{{model.homepage_url}}